## Vitor H Pomin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4796870/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Nuclear Magnetic Resonance Methods in Structural Characterization of Glycosaminoglycans. Methods in Molecular Biology, 2022, 2303, 183-207.	0.9	1
2	Safety and Pharmacokinetics of Intranasally Administered Heparin. Pharmaceutical Research, 2022, 39, 541-551.	3.5	3
3	Fractionation of sulfated galactan from the red alga Botryocladia occidentalis separates its anticoagulant and anti-SARS-CoV-2 properties. Journal of Biological Chemistry, 2022, 298, 101856.	3.4	13
4	Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. Journal of Virology, 2021, 95, .	3.4	176
5	Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus. Antiviral Research, 2021, 190, 105077.	4.1	19
6	Red Algal Sulfated Galactan Binds and Protects Neural Cells from HIV-1 gp120 and Tat. Pharmaceuticals, 2021, 14, 714.	3.8	5
7	Structural and kinetic analyses of holothurian sulfated glycans suggest potential treatment for SARS-CoV-2 infection. Journal of Biological Chemistry, 2021, 297, 101207.	3.4	31
8	Conformational properties of l-fucose and the tetrasaccharide building block of the sulfated l-fucan from Lytechinus variegatus. Journal of Structural Biology, 2020, 209, 107407.	2.8	7
9	Marine Antithrombotics. Marine Drugs, 2020, 18, 514.	4.6	16
10	Saturation Transfer Difference in Characterization of Glycosaminoglycan-Protein Interactions. SLAS Technology, 2020, 25, 307-319.	1.9	4
11	Biocompatibility and structural characterization of glycosaminoglycans isolated from heads of silver-banded whiting (Sillago argentifasciata Martin & Montalban 1935). International Journal of Biological Macromolecules, 2020, 151, 663-676.	7.5	9
12	Galactosaminoglycans: Medical Applications and Drawbacks. Molecules, 2019, 24, 2803.	3.8	34
13	Structural mechanisms involved in mild-acid hydrolysis of a defined tetrasaccharide-repeating sulfate fucan. , 2019, , 111-128.		2
14	Synthetic Oligosaccharide Libraries and Microarray Technology: A Powerful Combination for the Success of Current Glycosaminoglycan Interactomics. ChemMedChem, 2018, 13, 648-661.	3.2	24
15	Glycosaminoglycan-Protein Interactions by Nuclear Magnetic Resonance (NMR) Spectroscopy. Molecules, 2018, 23, 2314.	3.8	12
16	Marine Carbohydrate-Based Compounds with Medicinal Properties. Marine Drugs, 2018, 16, 233.	4.6	38
17	Anticoagulant and Antithrombotic Properties of Three Structurally Correlated Sea Urchin Sulfated Glycans and Their Low-Molecular-Weight Derivatives. Marine Drugs, 2018, 16, 304.	4.6	19
18	Glycosaminoglycans and Proteoglycans. Pharmaceuticals, 2018, 11, 27.	3.8	130

#	Article	IF	CITATIONS
19	NMR structural biology of sulfated glycans. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1069-1084.	3.5	20
20	The Sea as a Rich Source of Structurally Unique Glycosaminoglycans and Mimetics. Microorganisms, 2017, 5, 51.	3.6	38
21	Sulfated Glycans and Related Digestive Enzymes in the Zika Virus Infectivity: Potential Mechanisms of Virus-Host Interaction and Perspectives in Drug Discovery. Interdisciplinary Perspectives on Infectious Diseases, 2017, 2017, 1-8.	1.4	2
22	Sulfated Glycans in HIV Infection and Therapy. Current Pharmaceutical Design, 2017, 23, 3405-3414.	1.9	12
23	1H and 15N NMR Analyses on Heparin, Heparan Sulfates and Related Monosaccharides Concerning the Chemical Exchange Regime of the N-Sulfo-Glucosamine Sulfamate Proton. Pharmaceuticals, 2016, 9, 58.	3.8	9
24	NMRâ€based conformation and dynamics of a tetrasaccharideâ€repeating sulfated fucan substituted by different counterions. Biopolymers, 2016, 105, 840-851.	2.4	1
25	Dual and antagonic therapeutic effects of sulfated glycans. Bioorganic and Medicinal Chemistry, 2016, 24, 3965-3971.	3.0	12
26	Oligosaccharides from the 3-linked 2-sulfated alpha-L-fucan and alpha-L-galactan show similar conformations but different dynamics. Glycobiology, 2016, 26, 1257-1264.	2.5	7
27	Paradigms in the structural biology of the mitogenic ternary complex FGF:FGFR:heparin. Biochimie, 2016, 127, 214-226.	2.6	18
28	The contribution ofGlycobiologyto the Zika outbreak in the Americas. Glycobiology, 2016, 26, 680-682.	2.5	1
29	Phylogeny, structure, function, biosynthesis and evolution of sulfated galactose-containing glycans. International Journal of Biological Macromolecules, 2016, 84, 372-379.	7.5	11
30	Antimicrobial Sulfated Glycans: Structure and Function. Current Topics in Medicinal Chemistry, 2016, 17, 319-330.	2.1	18
31	A Dilemma in the Glycosaminoglycanâ€Based Therapy: Synthetic or Naturally Unique Molecules?. Medicinal Research Reviews, 2015, 35, 1195-1219.	10.5	34
32	Marine Non-Glycosaminoglycan Sulfated Glycans as Potential Pharmaceuticals. Pharmaceuticals, 2015, 8, 848-864.	3.8	34
33	Current structural biology of the heparin interactome. Current Opinion in Structural Biology, 2015, 34, 17-25.	5.7	50
34	Sulfated glycans in inflammation. European Journal of Medicinal Chemistry, 2015, 92, 353-369.	5.5	94
35	Sulfated glycans in sea urchin fertilization. Glycoconjugate Journal, 2015, 32, 9-15.	2.7	19
36	NMR structural determination of unique invertebrate glycosaminoglycans endowed with medical properties. Carbohydrate Research, 2015, 413, 41-50.	2.3	44

#	Article	IF	CITATIONS
37	Impact of sulfation pattern on the conformation and dynamics of sulfated fucan oligosaccharides as revealed by NMR and MD. Glycobiology, 2015, 25, 535-547.	2.5	19
38	Keratan sulfate: An up-to-date review. International Journal of Biological Macromolecules, 2015, 72, 282-289.	7.5	79
39	Medical Gains of Chondroitin Sulfate Upon Fucosylation. Current Medicinal Chemistry, 2015, 22, 4166-4176.	2.4	14
40	Biological findings from the recent NMR-based studies of glycosaminoglycan-protein interactions. Glycobiology, 2014, 24, 991-1003.	2.5	17
41	Marine medicinal glycomics. Frontiers in Cellular and Infection Microbiology, 2014, 4, 5.	3.9	22
42	Specific sulfation and glycosylationââ,¬â€a structural combination for the anticoagulation of marine carbohydrates. Frontiers in Cellular and Infection Microbiology, 2014, 4, 33.	3.9	36
43	Solution NMR conformation of glycosaminoglycans. Progress in Biophysics and Molecular Biology, 2014, 114, 61-68.	2.9	26
44	How to analyze the anticoagulant and antithrombotic mechanisms of action in fucanome and galactanome?. Glycoconjugate Journal, 2014, 31, 89-99.	2.7	7
45	Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug Discovery Today, 2014, 19, 1801-1807.	6.4	33
46	NMR-based dynamics of free glycosaminoglycans in solution. Analyst, The, 2014, 139, 3656-3665.	3.5	8
47	Unique Properties of Human β-Defensin 6 (hBD6) and Glycosaminoglycan Complex. Journal of Biological Chemistry, 2014, 289, 22969-22979.	3.4	18
48	NMR Chemical Shifts in Structural Biology of Glycosaminoglycans. Analytical Chemistry, 2014, 86, 65-94.	6.5	59
49	Anticoagulant motifs of marine sulfated glycans. Glycoconjugate Journal, 2014, 31, 341-344.	2.7	29
50	Holothurian Fucosylated Chondroitin Sulfate. Marine Drugs, 2014, 12, 232-254.	4.6	162
51	Heparin-Binding Proteins (Chemokines and Defensins) and their Complexes with Glycosaminoglycans from the Solution NMR Perspective. Current Protein and Peptide Science, 2014, 15, 738-744.	1.4	6
52	Sea, Carbohydrates and Clotting: A Triad on the Road of Drug Discovery. Mini-Reviews in Medicinal Chemistry, 2014, 14, 717-724.	2.4	8
53	Advances in glycosaminoglycanomics by 15N-NMR spectroscopy. Analytical and Bioanalytical Chemistry, 2013, 405, 3035-3048.	3.7	11
54	Marine Sulfated Glycans with Serpin-Unrelated Anticoagulant Properties. Advances in Clinical Chemistry, 2013, 62, 269-303.	3.7	16

#	Article	IF	CITATIONS
55	Exploiting enzyme specificities in digestions of chondroitin sulfates A and C: Production of well-defined hexasaccharides. Glycobiology, 2012, 22, 826-838.	2.5	38
56	Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges. Marine Drugs, 2012, 10, 793-811.	4.6	59
57	Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydrate Polymers, 2012, 90, 839-846.	10.2	42
58	Fucanomics and galactanomics: Current status in drug discovery, mechanisms of action and role of the well-defined structures. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1971-1979.	2.4	84
59	Structure–Function Relationship of Anticoagulant and Antithrombotic Well-Defined Sulfated Polysaccharides from Marine Invertebrates. Advances in Food and Nutrition Research, 2012, 65, 195-209.	3.0	27
60	Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Thrombosis and Haemostasis, 2010, 103, 994-1004.	3.4	75
61	Structural and functional insights into sulfated galactans: a systematic review. Glycoconjugate Journal, 2010, 27, 1-12.	2.7	91
62	Characterization of Glycosaminoglycans by <sup>15</sup> N NMR Spectroscopy and in Vivo Isotopic Labeling. Analytical Chemistry, 2010, 82, 4078-4088.	6.5	51
63	Unique Extracellular Matrix Heparan Sulfate from the Bivalve Nodipecten nodosus (Linnaeus, 1758) Safely Inhibits Arterial Thrombosis after Photochemically Induced Endothelial Lesion. Journal of Biological Chemistry, 2010, 285, 7312-7323.	3.4	60
64	A Unique 2-Sulfated β-Galactan from the Egg Jelly of the Sea Urchin Glyptocidaris crenularis. Journal of Biological Chemistry, 2009, 284, 18790-18800.	3.4	44
65	Review: An overview about the structure–function relationship of marine sulfated homopolysaccharides with regular chemical structures. Biopolymers, 2009, 91, 601-609.	2.4	106
66	Structure, biology, evolution, and medical importance of sulfated fucans and galactans. Glycobiology, 2008, 18, 1016-1027.	2.5	288
67	A preponderantly 4-sulfated, 3-linked galactan from the green alga Codium isthmocladum. Glycobiology, 2007, 18, 250-259.	2.5	98
68	Mild acid hydrolysis of sulfated fucans: a selective 2-desulfation reaction and an alternative approach for preparing tailored sulfated oligosaccharides. Glycobiology, 2005, 15, 1376-1385.	2.5	84
69	Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II–dependent anticoagulant activity. Glycobiology, 2005, 15, 369-381.	2.5	109
70	Inhibition of SARS-CoV-2 wild-type (Wuhan-Hu-1) and Delta (B.1.617.2) strains by marine sulfated glycans. Glycobiology, 0, , .	2.5	5